Luca Mastorino is an expert in Dermatology at University of Turin (Italy). Luca Mastorino has authored 166 publications, the most recent in 2026. SLR score: 547 (community average: 125). How the SLR is computed.

LeadR Profile

Luca Mastorino University of Turin Italy
547 ScienceLeadR Reputation 547
Network Map

Dermatology

Subspecialties: Public Health - Biochemistry - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2020 - 2026

Source: PubMed

University of Turin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 166

Citations

Citations: 1 052 1st author: 51 Last author: 8 Unique author: 1


Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
PMID 42858399 — interleukin-23, therapeutics, psoriasis, interleukin-17
Dermatol Pract Concept20260
Real-World Strategies for Biologic Dose Escalation and Reduction in Psoriasis and Psoriatic Arthritis: A Systematic Review.
PMID 42806636 — arthritis, psoriatic, ustekinumab, interleukin-12, arthritis, skin diseases, drug tapering, adalimumab, etanercept, therapeutics, biological therapy, psoriasis, dermatology, infliximab
J Cutan Med Surg20260
Omalizumab Discontinuation in Chronic Spontaneous Urticaria: Effectiveness and Predictors of Response and Relapse Comparing Abrupt Cessation and Dose Spacing in a Retrospective Real-Life Study.
PMID 42786691 — omalizumab, urticaria, drug tapering, therapeutics, dermatology
J Cutan Med Surg20260
Patient-Level Cumulative Clinical Benefit of Brodalumab Over 52 Weeks: A Multicentre Real-World Study-IL PSO (Italian Landscape Psoriasis).
PMID 42754803 — therapeutics, psoriasis
Dermatol Ther (Heidelb)20260
Site-Specific Response and Psychosocial Outcomes in Head and Neck Atopic Dermatitis Treated with Tralokinumab: A Prospective Real-World Study.
PMID 42723567 — quality of life, dermatitis, eczema, pruritus, dermatitis, atopic, dermatitis, contact
Dermatitis20260

LeadR Networks

Main global connection map